Results 41 to 50 of about 44,894 (310)

CYP2D6-polymorphism and effect of adjuvant tamoxifen in breast cancer patients

, 2023
Adjuvant tamoxifen at the standard dose of 20 mg daily for five to ten years reduces the risk for relapse and mortality in hormone sensitive breast cancer. The effect however varies and no early marker of poor response is yet available.
Linda Thorén (18661456)
core   +1 more source

CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations

Neuropsychiatric Disease and Treatment, 2022
Yong-Hang Li,1,* Wei Huang,1,* Man-Yu Xiao,2 Shi-Qing Huang,1 Hui Chen,1 Zai-Fang Li,1 Xue-Song Li,1 Yong Cheng1,2 1The Third People’s Hospital of Foshan, Foshan, Guangdong, People’s Republic of China; 2Center on Translational Neuroscience ...
Li YH, Huang W, Xiao MY, Huang SQ, Chen H, Li ZF, Li XS, Cheng Y   +7 more
doaj  

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

Cancers, 2021
Simple Summary Tamoxifen is an important adjuvant endocrine therapy in estrogen receptor (ER)-positive breast cancer patients. It is mainly catalyzed by the enzyme CYP2D6 into the most active metabolite endoxifen.
Tessa A. Mulder, Mirjam de With, M. Del Re, R. Danesi, R. Mathijssen, R. V. van Schaik   +5 more
semanticscholar   +1 more source

CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis

Терапевтический архив, 2022
Aim. To study the polymorphic markers CYP2D6*4 (G1846A, rs3892097), CYP2D6*6 (T1707del, rs5030655), CYP2D6*10 (C100T, rs1065852), CYP2D6*41 (G2988A, rs28371725) and CYP2D6*3 (A2549del, rs4986774) role in treatment optimization of portal hypertension with
Dmitry A. Sychev, Andrei I. Parusov, Irina D. Loranskaya, Natalia P. Denisenko, Kristina A. Akmalova, Zhannet A. Sozaeva, Olga L. Turkina, Michael S. Zastrozhin   +7 more
doaj   +1 more source

Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity

British Journal of Pharmacology, 2021
Individualized assessment of cytochrome P450 2D6 (CYP2D6) activity is usually performed through phenotyping following administration of a probe drug to measure the enzyme's activity.
G. Magliocco, J. Desmeules, A. Matthey, L. Quirós-Guerrero, N. Bararpour, Timothée Joye, L. Marcourt, E. Queiroz, J. Wolfender, Y. Gloor, Aurélien Thomas, Y. Daali   +11 more
semanticscholar   +1 more source

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population

Frontiers in Pharmacology, 2017
Purpose: Asian populations have around 40–60% frequency of reduced function allele CYP2D6∗10 compared to 1–2% in Caucasian populations. The wide range of CYP2D6 enzyme activities in subjects with the CYP2D6∗10 variant is a big concern for clinical ...
Pei Hu, Rui Chen, Xin Zheng
doaj   +1 more source

CYP2D6 in the Brain: Potential Impact on Adverse Drug Reactions in the Central Nervous System—Results From the ADRED Study

Frontiers in Pharmacology, 2021
Cytochrome P450 (CYP) 2D6 is a polymorphic enzyme expressed in the central nervous system (CNS), important in drug metabolism and with a potentially constitutive role in CNS function such as vigilance.
Katja S. Just, Harald Dormann, Mathias Freitag, Marlen Schurig, Miriam Böhme, Michael Steffens, Catharina Scholl, Thomas Seufferlein, Ingo Graeff, Matthias Schwab, Matthias Schwab, Matthias Schwab, Julia C. Stingl   +12 more
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update

Clinical pharmacology and therapy, 2017
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline,
J. K. Hicks, K. Sangkuhl, J. Swen, V. Ellingrod, Daniel J. Müller, K. Shimoda, J. Bishop, E. Kharasch, T. Skaar, A. Gaedigk, H. M. Dunnenberger, T. E. Klein, K. Caudle, J. Stingl   +13 more
semanticscholar   +1 more source

Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates

Clinical pharmacology and therapy, 2021
The metabolic activity of the polymorphic CYP2D6 enzyme is dependent on the CYP2D6 genotype; however, the guidelines for translating the genotype into phenotype, which are of relevance for adequate drug dose personalization, are ambiguous. In the present
Marin M. Jukić, R. L. Smith, E. Molden, M. Ingelman-Sundberg   +3 more
semanticscholar   +1 more source

CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico [PDF]

, 2014
Aim: Polymorphisms in CYP2D6 impact the interindividual and interethnic variability of drug efficiency; therefore, we determined the CYP2D6 allele distribution in eight Amerindian groups from northwestern Mexico and compared them with the frequencies in ...
Llerena, Adrián, Martínez Fierro, Margarita de la Luz, Galaviz Hernández, Carlos, Garza Veloz, Idalia, Lazalde Ramos, Blanca Patricia, Naranjo, María Eugenia, Sosa Macías, Martha   +6 more
core   +1 more source